In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

The OPTION trial showed equivalence between Watchman FLX and oral anticoagulation in preventing stroke, systemic embolism, and all-cause death post-ablation. Subgroup analyses revealed consistent ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

Study suggests a path forward for device therapy, though caveats are plenty ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

Boston Scientific, an MD+DI Medtech Company of the Year finalist, announced positive three-year primary endpoint results over the weekend from the OPTION global clinical trial of its Watchman Flx left ...

MARLBOROUGH, Mass., May 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, ...